WALTHAM, Mass., Dec. 3 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) today announced the FDA clearance of an IND
application for a cocaine vaccine therapeutic product.
    "The IND was filed on October 29, 1997 in preparation for a planned
Phase I clinical trial for the first quarter 1998" said Joseph Marr, M.D.,
President and Chief Operating Officer of ImmuLogic Pharmaceutical Corporation.
"There are currently no medications approved specifically for treating cocaine
addiction.  The vaccine technology is a novel approach to address the unmet
need in substance abuse treatment."
    ImmuLogic previously reported the award of a $2.2M grant from the National
Institute on Drug Abuse to fund development of the cocaine vaccine for the
treatment of cocaine addiction.
    The cocaine vaccine therapeutic is based on vaccination of cocaine addicts
with a cocaine-protein conjugate.  The treatment is expected to induce an
anti-cocaine antibody response which reduces the entry of cocaine into the
brain.  As a result, it is anticipated that the psychopharmacological effect
of the drug will be reduced.  The product is designed to be used in
conjunction with a behavioral modification treatment program.
    ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, Massachusetts, focused on developing treatments for
allergies and substance abuse.  The Company's press releases are available
through Company News on Call by fax at 800-758-5804, ext. 114501, and on the
Internet at http://www.prnewswire.com.
    This press release, contains forward-looking statements that involve a
number of risks and uncertainties.  Among the most important factors that
could cause actual results to differ materially from those indicated by such
forward-looking statements are delays in product development, failure to
obtain required regulatory approvals, and the risk factors detailed in the
Company's Annual Report on Form 10-K for the year ended December 31, 1996.

Link to this page: